Documentdetail
ID kaart

doi:10.1186/s12916-022-02442-w...

Auteur
Cui, Can Sun, Jiangwei McKay, Kyla A. Ingre, Caroline Fang, Fang
Langue
en
Editor

BioMed Central

Categorie

Medicine & Public Health

Jaar

2022

vermelding datum

10-08-2022

Trefwoorden
medication amyotrophic lateral sclerosis risk association articles systematic included risk studies als medication review drugs
Metriek

Beschrijving

Background Studying whether medications act as potential risk factors for amyotrophic lateral sclerosis (ALS) can contribute to the understanding of disease etiology as well as the identification of novel therapeutic targets.

Therefore, we conducted a systematic review to summarize the existing evidence on the association between medication use and the subsequent ALS risk.

Methods A systematic review was conducted in Medline, Embase, and Web of Science from the date of database establishment to December 10, 2021.

References of identified articles were further searched for additional relevant articles.

Studies were included if (1) published in English, (2) explored medication use as exposure and development of ALS as outcome, and (3) the design was a human observational study.

Clinical trials, reviews, comments, editorials, and case reports were excluded.

Quality assessment was performed using a pre-validated tool for non-randomized studies, the Newcastle–Ottawa Assessment Scale (NOS).

Results Of the 4760 studies identified, 25 articles, including 13 case–control studies, five nested case–control studies, six cohort studies, and one retrospective chart review, were included in the review.

Among these studies, there were 22 distinct study populations that included 171,407 patients with ALS, seven classes of medication examined, and 23 studies with a NOS ≥ 5.

There was a general lack of agreement between studies on the associations of cholesterol-lowering drugs, anti-inflammatory drugs, immunosuppressants, antibiotics, oral contraceptives (OCs) or hormone replacement therapy (HRT), antihypertensive drugs, antidiabetics, and drugs for psychiatric and neurological disorders with the subsequent risk of ALS.

However, it appeared that statins, aspirin, OCs/HRT, antihypertensives, and antidiabetics were unlikely related to a higher risk of ALS.

The positive associations noted for antibiotics, antidepressants, and skeletal muscle relaxants might be attributable to prodromal symptoms of ALS.

Conclusions There is currently no strong evidence to link any medication use with ALS risk.

Cui, Can,Sun, Jiangwei,McKay, Kyla A.,Ingre, Caroline,Fang, Fang, 2022, Medication use and risk of amyotrophic lateral sclerosis—a systematic review, BioMed Central

Document

Openen

Delen

Bron

Artikelen aanbevolen door ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw